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ABSTRACT 
Background: Previous studies have shown high prevalence of HCV infection among people 
living with HIV infection. Coinfected people are at risk of developing liver diseases resulting an 
increase rate of mortality. Several risk factors for HIV/HCV coinfection have previously been 
identified with injecting drug users (IDU) as the common route of exposure.  
Methods:  This was cross -sectional study using HIV and HCV registries maintained by 
Nebraska Department of Health and Human Services (NE DHHS) from1997 to 2017. A 
descriptive analysis was used to characterize the sample. Chi-squared test and Fisher exact test 
were selected to compare the different groups. Univariate and multiple variable logistic 
regression model chose for the analytical analysis for association between variables. 
Results: Of 3256 persons with HIV, 356 were coinfected with HCV resulting a proportion of 
11%. Based on HIV diagnosis, 52% persons were coinfected by HCV after being diagnosed with 
HIV while 48% acquired their HCV before becoming infected with HIV. Exposure by IDU 
(OR=3.8, 95% CI:2.6-6.7), IDU & Heterosexual contact (OR=3.3, 95% CI:1.8-5.8), MSM & 
heterosexual contact (OR=2.7, 95% CI:1.1-6.7), MSM & IDU (OR=4.5, 95% CI:2.7-7.5) and  all 
three factors MSM & IDU & Heterosexual contact (OR=4.8, 95% CI:2.1-11.1) had higher odds 
of HIV/HCV coinfection compare to heterosexual contact alone. MSM alone was not a 
statistically significant risk factor for coinfection. The 56 years and above age group had highest 
odds of HCV coinfection. Moreover, coinfected persons had 1.87 odds of dying (95% CI: 1.42-
2.45) compared to those with HIV alone.  
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BACKGROUND 
HIV and HCV infections are major global public health problems with overlapping 
modes of transmission and overlapping affected populations (WHO, 2018). Chronic infection 
with these viruses is among the greatest challenges facing health care systems in the United 
States and worldwide (Hadigan & Kottilil, 2011). Globally, there are an estimated 36.9 million 
people living with HIV infection and 1.8 million people were newly infected with HIV during 
2017 (UNAIDS, 2018).  Hepatitis C prevalence is even higher, with an estimated 115 million 
people with chronic infection worldwide (WHO,2018) & (Smith & Sterling, 2007). Looking to 
HIV/HCV coinfection, the WHO reported that approximately 2.3 million people living with HIV 
are coinfected with hepatitis C virus (HCV) worldwide with 1.3 million of those injecting drugs 
(persons who inject drugs; PWID) (WHO, 2018).  
Overall, it is estimated that HCV infection affects 2–15% of people living with HIV 
worldwide (and up to 90% of those are PWID) and the burden of these co-infections is greatest 
in the African and South East Asia Regions (WHO, 2018). The sub-Saharan African region 
accounts for the majority of HIV/HCV coinfection worldwide due to the high burdens of HIV in 
this location (Platt et al., 2016).  A study also found that HIV-infected people are on average six 
times more likely than HIV-uninfected people to have HCV infection; furthermore, among 
people living with HIV infection, the rates of HCV coinfection are elevated among MSM (6.4%) 
and among PWID can be as high as 82·4% Platt et al., 2016) &(Cuomo et al., 2018).  
In studies from Western Europe and the USA, HCV infection has been found in 25–30% 
of HIV-positive persons overall; 72–95% of injection drug users, 1–12% of MSM and 9–27% of 
5 
 
heterosexuals (Alter, 2006) and Thomas reported that HCV coinfection occurs in one quarter of 
HIV-infected persons in Europe, Australia, and the United States (Thomas, 2008). HCV is the 
cause of more than three-quarters of liver-related deaths among people living with HIV infection, 
Nowadays, approximately one-quarter of HIV-infected individuals in Europe and the USA have 
HCV coinfection (d'Arminio Monforte et al., 2009). 
In the U.S, the CDC estimates that one quarter of people living with HIV infection in the 
United States are also infected with HCV, a bloodborne virus transmitted through direct contact 
with the blood of an infected person (CDC, 2018). But a study using surveillance data from 15 
states and two cities in the US which collected data from 504 398 persons living with diagnosed 
HIV infection at the end of 2014, showed that only 6.7% were coinfected with HCV (Bosh et al., 
2018).  The CDC also notes that, in the U.S, HIV/HCV confection is common (50%–90%) 
among injection drug users (CDC, 2018).  
Many other risk factors and demographic characteristics have been associated with a risk 
of HCV coinfection among people living with HIV. These include: being in prison, low 
socioeconomic status, the presence of one or more tattoos, a history of trading sex for money or 
drugs, having 11 or more sexual partners, and having sex with an intravenous drug user. But in 
England, a study showed that the majority acquired HIV and HCV through sex between men 
64.9%, followed by injecting drug use; 22.5% and heterosexual contact 12.4% (Ireland et al., 
2018).   
Since 2000 there has been recognition in developed countries that there has been a 
dramatic rise in the incidence of HCV among people living with HIV, especially in the group of 
MSM (Men who have sex with Men) even though sexual transmission of HCV remains 
controversial in the general population (Danta & Rodger, 2011). Bollepalli et al., using a 
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multivariate regression model, concluded that only intravenous drug use is a significant risk 
factor/predictor of HCV/HIV coinfection (Bollepalli et al., 2007). 
HIV/HCV Coinfection is associated with high morbidity and mortality, making identification of 
these cases crucial as HCV infection progresses more rapidly to liver damage among HIV-
infected persons (CDC,2018).  Compared to people living with HIV but without HCV, HCV 
coinfected patients were more likely to develop cirrhosis, had an increased risk of developing 
AIDS, of HIV-related disease and of overall mortality (Andreoni et al., 2012).  
Individuals who are coinfected with both viruses are at risk for accelerated liver disease 
and consequently cirrhosis, liver failure, and hepatocellular carcinoma with a high rate of 
mortality, especially in developing countries (Operskalski & Kovacs, 2011) & (Matthews & 
Dore, 2008). Despite tremendous advances in treatment and management of HIV and HCV, 
individuals with HIV/HCV coinfection experience a more complicated disease course (Hadigan 
& Kottilil, 2011). Complications due to the coinfection are accountable for an approximate 30% 
reduction in life expectancy among people who live with these two chronic infections 
(Leszczyszyn-Pynka et al., 2018). 
In Nebraska, there is a need for current studies examining the burden and risk factors 
associated with HCV coinfection among people infected with HIV infection. This study was 
undertaken in order to gain an improved understanding of the HIV/HCV coinfection burden in 
Nebraska with the expectation that interventions by relevant health authorities could be better 
focused and made more efficient in order to prevent and decrease the burden of HCV coinfection 
among people infected with the HIV infection. 
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In this study we aimed to determine:  
1) The prevalence and the sociodemographic characteristics of HCV coinfection among 
people living with HIV infection in Nebraska from 1997 to 2017 
2) The temporal and spatial distribution of HCV coinfection among people living with 
HIV infection in Nebraska from 1997 to 2017  
3) The risk factors for HCV coinfection among people living with HIV in Nebraska 
from 1997 to 2017  
 
METHODS 
Study design and data sources 
This was a cross-sectional study using surveillance data from separate HIV/AIDS and 
HCV registries. The HIV/AIDS data is stored in the Enhanced HIV/AIDS Reporting System 
(eHARS) which is a browser-based, CDC-developed application that assists health departments 
with data reporting, data management, and data transfer to CDC.  
All Electronic Lab Reports (ELR) are received by the Nebraska Diseases Surveillance 
System (NEDSS), which is the web-based disease surveillance system for most reportable 
diseases including HCV and HIV.  Prior to the NEDSS, the reportable diseases were stored in the 
Telecommunications System for Surveillance (NETSS). The HIV lab reports are then imported 
into eHARS using a CDC-developed import process through SAS software.  
To obtain the final dataset which contains all HIV patients having positive lab report for 
hepatitis C, we merged the three datasets (NETSS, NEDSS and eHARS) and then de-identified 
using a unique identifier for everyone represented in the dataset using SAS.   
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Approval for the study was obtained from the Institutional Review Board (IRB) at the 
University of Nebraska Medical Center and all patient data was de-identified to avoid any risk to 
patient confidentiality. 
 
Eligibility criteria 
The merging process of the registries generated a dataset of 5288 patients from 1983 to 
2018. This original dataset contains all the newly diagnosed patients with HIV/AIDS and 424 
were coinfected with HCV.  
After, applying the following selection criteria: 
• People newly diagnosed with HIV infection between 1997 to 2017. The implementation 
of highly active antiretroviral therapy (HAART) in 1996 dramatically altered the life 
expectancy, and potentially the behavior, of HIV-infected individuals. Patients with much 
longer expectancies have more time and opportunities to acquire additional infections 
such as HCV infection. We thus chose to limit our study to the HAART era 
• Reported and enrolled as person living with HIV/AIDS in Nebraska at DHHS registries.  
• Person HIV infected, tested for hepatitis C and the result reported to the NE-DHHS  
The final dataset contains 3236 people living with HIV and 356 coinfected with HCV 
 
Modeling and Statistical analysis  
This study is divided in three parts as following: 
• A descriptive analysis was conducted in order to summarize the characteristics of the 
study sample, including sociodemographic characteristics and effects of HCV coinfection 
among people living with HIV. This was accomplished by comparing the different 
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proportions (percentage) of people living with HIV infection and those with the 
coinfection HIV/HCV. Frequencies were generated to compare the different groups.  
• Our study focused on describing the characteristics of those with the coinfection 
HIV/HCV and identified risk factors associated with HCV coinfection among HIV 
infected patients. Univariate and multiple logistic regression analyses were conducted in 
order to assess the influence of these risk factors. 
•  Finally, a descriptive analysis was conducted in order to compare people diagnosed as 
having HCV before HIV with those who acquired HCV after receiving an HIV diagnosis.  
All variables were transformed to categorical variables and patients were stratified in specific 
groups to reduce interaction and confounding effects.  Fisher’s exact test was used for the 
descriptive analysis. The Interaction among the following variables was checked and all analysis 
was conducted using SAS 9.4. The alpha level of 0.05 and confidence interval excluding 1 were 
used to determine the statistical significance. ArcGIS was used to determine the geographical 
distribution of HIV/HCV coinfected patients within Nebraska. 
 
Variables: 
The principle outcome variable in our study was HIV/HCV Coinfection. A person with 
HIV/HCV coinfection is defined as someone who has both infections.  The main exposures 
(transmission categories) were grouped into MSM only, IDU only, Heterosexual contact, MSM 
and IDU, MSM & Hetero, IDU and Hetero, MSM & IDU & Hetero, and other (Perinatal, No 
Identified Risk, No Reported Risk). 
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RESULTS 
Of a total 3236 persons reported to the NE-DHHS from 1997 to 2017 as persons living 
with HIV/AIDS and 356 people were coinfected with HCV as result, the estimated proportion of 
HCV among people living with HIV/AIDS was around 11%.                                                                  
 
Figure 1 below represents the percentage per year of HCV coinfection among PLWHA in 
Nebraska with an overall increase from 1997 to 2015 and a slight decrease since 2015 
 
Figure 1: Proportion(percentage) of HCV infection among PLWHA in Nebraska, 1997- 
2017 
Figure 2 and 3 below shows the geographical repartition of HIV infection and HIV/HCV 
coinfection in Nebraska during 1997 to 2017. Most of reported cases of HIV/AIDS infection and 
HIV/HCV coinfection were in Douglas and Lancaster health districts.   
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
11 
 
 
Figure 2: Distribution of HIV infection only per health district between 1997 to 2017 Nebraska 
Figure 3: Distribution of HCV/HIV coinfection per health district between 1997 to 2017, in 
Nebraska 
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Table 1 describes the characteristics of people living with HIV infection and those living with 
HIV/HCV coinfection. The total number of people living with HIV/AIDS (PLWHA) was 3236 
and 356 persons were coinfected.   Non- Hispanic whites represented over 50% of cases and 
non-Hispanic blacks composed around the third of cases. The proportion of Hispanics among 
PLWHA was found to be15% vs 8% for HIV/HCV coinfection. 
 Males accounted for approximately 80% of cases of PLWHA, as well as 80% of 
coinfected people.  Men who sex with men (MSM) represent 46.5% of PLWHA and only 39 % 
for coinfected persons. A heterosexual exposure was found in 15.9% among PLWHA compared 
to 9.5% for people coinfected with HCV.  The proportion of injection drugs users (IDU) was 3 
times higher among people with coinfection HCV compared to those with HIV infection only. 
There was no identified risk or reported risk in 24.4% of PLWHA and 18% of coinfected 
patients.  
When examining by age, approximately 2/3 of cases were between 26 to 45 years, with a 
tendency towards older age among people with HIV/HCV coinfection. The percentage of 
foreign-born individuals was 28.4% among PLWHA vs 17.3% for those with coinfection. The 
stage of HIV infection was similar between the two groups, but the number of deaths was 
approximately twice as high (22.7% vs 13.6%) among people with coinfection compared to 
those with HIV only. 
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Table 1: Descriptive characteristics of people living with HIV/AIDS vs People coinfected with 
HCV in Nebraska from 1997 to 2017 
 HIV only (%) HIV/HCV (%) 
Race   
White 1482(51.4) 207 (58.1) 
Black 798 (27.7) 96 (26.9) 
Hispanic 426(14.7) 30 (8.4) 
Asian 62(2.1) 5(1.4) 
Multi-race 54(1.8) 10(2.8) 
Other (AI/AN, NHw/PI) 58(2) 8(2.2) 
Gender   
Male 2245(78) 268(75.3) 
Female 635(22) 88(24.7) 
Exposure   
MSM only 1339(46.5) 139(39) 
IDU only 94(3.2) 31(8.7) 
Heterosexual only 459(15.9) 34(9.5) 
MSM and IDU 130(4.5) 44(12.3) 
IDU and Hetero 94(3.2) 27(7.6) 
MSM & Hetero 33(1.1) 7(2) 
MSM & IDU & Hetero 27(0.9) 10(2.8) 
Other 704(24.4) 64(18) 
Age group   
Less than 16 55(1.91) 1(0.28) 
17-25 555(19.2) 48(13.4) 
26-35 1029(35.7) 100(28) 
36-45 768(26.6) 129(36.2) 
46-55 374(13) 60(16.8) 
56 and above 99(3.4) 18(5) 
Birth Country    
USA 2058 (71.4) 295(82.9) 
Foreign 822(28.5) 61(17.1) 
State of HIV diagnostic   
Nebraska 1844(64) 207(58.1) 
Non-Nebraska 1036(36) 149(41.8) 
HIV stage   
Acute HIV 1378(47.8) 158(44.4) 
Clinical Latency  1493(51.8) 198(55.6) 
AIDS 9(0.31) 0(0) 
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Vital Status   
Alive  2484(86.4) 275(77.2) 
Death 391(13.6) 81(22.7) 
Total 2880 356 
Other/Exposure: (Perinatal, No Identified Risk, No Reported Risk, Sharing Sex Toys, etc.); 
other/Race: (Native Hawaiian/Pacific Islander, Native American/Alaska Natives).   
 
Table 2 shows odds ratios associated with different characteristics and risk factors of HIV/HCV 
coinfected people. Among the variables considered in the model, using heterosexual contact only 
as reference group, MSM had 1.4 times odds of HIV/HCV coinfection but this estimate was not 
statistically significant (CI=0.9-2.1). However, IDU, IDU & Hetero, MSM & hetero, MSM & 
IDU, MSM & IDU & Hetero had a significant increase in the odds of HIV/HCV coinfection with 
respective odds ratios of 3.8, 3.3, 2.7, 4.5 and 4.8. Referring to the 17-26 years age group as a 
reference, 36-45 years old (OR=1.7, 95% CI: 1.2-2.5), 46-55 years old (OR=1.7,95% CI: 1.1-
2.6) and 56 years old and above (OR=2.1, 95% CI: 1.1-3.7) had significantly increased odds of 
having HIV/HCV coinfection. Based on the birth country and comparing to USA born, foreign 
born had 0.7 odds of having HIV/HCV coinfection, this estimated was statistically significant 
(OR=0.7, 95% CI=0.4-0.9).  
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Table 2: Multivariable analysis results summarizing the odds ratio of HIV/HCV 
coinfection 
 Crude OR 95% Wald CI 
Race   
Asian vs White  1.1 0.4-3.1 
Black vs White 1.2 0.9-1.6 
Hispanic vs White 0.8 0.5-1.27 
Multi-race vs White 1.7 0.8-3.5 
Other vs White 0.8 0.3-1.8 
Exposure category      
MSM vs Hetero 1.4 0.9-2.1 
IDU vs hetero 3.8 2.2-6.7 
IDU & Hetero vs Hetero 3.3 1.8-5.8 
MSM & Hetero vs Hetero 2.7 1.1-6.7 
MSM & IDU vs Hetero 4.5 2.7-7.5 
MSM & IDU & Hetero vs Hetero 4.8 2.1-11.1 
Other vs Hetero 1.4 0.9-2.1 
Birth sex       
Female vs Male 1.2 0.9-1.6 
Age group   
26-35 vs 17-25 1.1 0.7-1.6 
36-45 vs 17-25 1.7 1.2-2.5 
46-55 vs 17-25 1.7 1.1-2.6 
56-above vs 17-25 2.1 1.1-3.7 
Less than 16 vs 17-25 0.2 0.0-1.8 
Birth Country   
Foreign vs USA 0.7 0.4-0.9 
State   
Non-Nebraska vs Nebraska 1.2 0.9-1.5 
 
Table 3 summarizes the descriptive characteristics of HIV/HCV coinfected people based on the 
timing of HIV diagnosis. Of a total 356 coinfected cases, 248 had enough information to enable a 
determination as to which infection was diagnosed first. Of those 248 persons, 129 were 
diagnosed with HCV after the HIV and 119 were diagnosed with HCV before HIV infection. 
The proportion among different races/ethnicities was approximately similar between people 
having the HCV before or after HIV infection started. There was not a significant difference in 
gender between the two groups. When considering exposure, IDU was twice as prevalent among 
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people diagnosed with HCV before HIV compared to those diagnosed with HCV after HIV. The 
proportion of people over 46 years old having HCV before HIV was 2 times higher than those 
having HCV after HIV infection.  The proportion of Non-Nebraskans (moved from another state 
to Nebraska) who contracted their HCV infection after HIV was approximately twice that of 
those who were infected with HCV first.  
 
Table 3: Descriptive analysis of HIV/HCV coinfection comparing HCV diagnosed after 
HIV onset vs HCV diagnosed before HIV      
 HCV after HIV HCV before HIV 
Race   
White 74(57.3) 76(63.8) 
Black 34(26.3) 27(22.7) 
Hispanic 10(7.7) 11(9.2) 
Asian 2(1.5) 2(1.7) 
Multi-race 6(4.6) 0(0) 
Other (AI/AN, NHw/PI)  3(2.3) 3(2.5) 
Gender   
Male 98(76) 96(80.7) 
Female 31(24) 23(19.3) 
Exposure   
MSM only 61(47.3) 46(38.6) 
IDU only 7(5.4) 12(10.1) 
Heterosexual only 12(9.3) 12(10.1) 
MSM and IDU 14(10.8) 11(9.2) 
IDU and Hetero 9(7) 4(3.3) 
MSM & Hetero 1(0.8) 3(2.5) 
MSM & IDU & Hetero 4(3.1) 1(0.8) 
Other 21(16.3) 30(25.2) 
Age group   
Less than 16 0(0) 1(0.8) 
17-25 23(17.8) 16(13.4) 
26-35 42(32.5) 31(26) 
36-45 46(35.6) 38(31.9) 
46-55 14(10.8) 24(20.2) 
56 and above 4(3.1) 9(7.5) 
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Birth Country    
USA 105(81.4) 98(82.3) 
Foreign 24(18.6) 21(17.6) 
State of HIV diagnostic   
Nebraska 71(55) 96(80.7) 
Non-Nebraska 58(45) 23(19.3) 
Total 129 119 
HIV stage   
Acute HIV 51(39.5) 58(48.7) 
Clinical Latency  78(60.5) 61(51.3) 
AIDS 0(0) 0(0) 
Vital Status   
Alive  94(72.9) 93(78.2) 
Death 35(27.1 26(21.8) 
 129 119 
Estimated mortality: in a univariate analysis with death as the outcome, coinfected HCV/HIV 
had 1.87 odds of dying compare to those with HIV infection only (OR=1.87; 95% CI: 1.42-
2.45).  
 
DISCUSSION 
Our study found an estimated proportion of HCV infection among PLWHA of 11%, this 
proportion is less than the overall estimate reported by the Centers for Disease Control and 
Prevention (2018) of about 25% and less than the 25-30% reported by Alter et al. (2006) in 
Europe and the U.S. In contrast, a population-based study using surveillance data from 15 states 
in the US and involving 504,398 persons living with diagnosed HIV infection in 2014, revealed 
that only 6.7% were coinfected with HCV (Bosh et al., 2018). This study estimated the 
proportion of HCV among newly diagnosed HIV infection which may explain the differences 
with other studies referring to the prevalence or the incidence rate. 
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The incidence of HIV/AIDS infection has declined over the past two decades, but the 
prevalence of HCV coinfection increased over the past two decades in Nebraska. This trend was 
corroborated by Smith & Sterling (2007) who also reported an increase in acute HCV from 
2007 to 2010. According to Hagan et al. (2002) and Edlin, Eckhardt, Holmberg & Swan (2015), 
public health surveillance tools may misrepresent the true rates due to under-reporting of cases 
of high-risk groups and because better programs of screening may explain the constant 
increase in the number of HCV cases reported to health authorities. Since 2015, a decrease of 
proportion of notified cases has been seen, but future investigations are needed in order to 
understand the real cause of this diminution. 
Most cases of HIV/HCV coinfection were reported in the Douglas and Lancaster 
County health districts; this is almost certainly due to the number of people in these two 
counties, which account for around 50% of persons of all Nebraska according to Nebraska 
Department of Health and Human Services (2015).  
This study showed that non-Hispanic Whites represented approximately two thirds of 
all cases and non-Hispanic Blacks represented approximately one quarter of all cases. In 
Nebraska, 80% of people are non-Hispanic white and 4.7% are non-Hispanic Black (Nebraska 
Department of Health and Human Services, 2015); therefore, Blacks seem to have a high 
incidence than whites in both the PLWHA and HCV coinfection groups).  Silverberg, Leyden, 
Quesenberry & Horberg (2009) found similar results in a retrospective cohort study of 4,686 
HIV-infected patients. Multivariate analysis of our data showed that the odds of having HCV 
coinfection was not statistically significantly different when comparing whites to other races. 
In England, a study based on national surveillance using Public Health England HIV/AIDS 
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database, Blacks had a 3.19-fold increase in the odds of having HIV/HCV coinfection. (Ireland 
et al., 2018)  
The ratio of males to females was approximately 4:1 among PLWHA and among those 
coinfected with HCV. A similar study using surveillance data in New York obtained 
approximately the same results males accounting for 70-80% of those living with HCV 
coinfection (Prussing et al., 2015). Comparing female and males, the odds of having HCV 
coinfection was not statistically significant (OR=1.2; 95% CI 0.9-1.6; see table).  
This study showed that most people in Nebraska were infected because they were Men 
who have Sex with Men (MSM) and/or Injection Drug Users (IDU). Around 40% of HCV 
coinfected individuals acquired their infections through MSM and over 40% were IDU in 
addition to other types of exposure. In the multivariate analysis, using heterosexual as reference, 
IDU only, IDU & Hetero, MSM & Hetero, MSM & IDU, MSM & IDU & Hetero had significant 
odds of having HCV coinfection (Table 3).  
MSM had 1.4 times the odds of HIV/HCV coinfection compared to the Hetero group, but 
this estimate was not significant (CI=0.9-2.1). Several authors have corroborated these findings, 
Bollepalli et al. (2007) found that HCV coinfection was associated with IDU but not with sexual 
risk factors   and the distribution of sterile needles produced a decline in the prevalence of HIV 
among IDU (Burt & Thiede,2016). Another study showed that there was a low prevalence of 
HCV coinfection among non-IDU with high-risk sexual behavior, similar to our conclusions 
regarding MSM. (Chew et al., 2015).  The Centers for Disease Control and Prevention (2011) 
reported that 59.9% of hepatitis cases were associated with the use of injection drugs and only 
12.9% were associated with sexual exposures.  
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There was a difference in the distribution of HIV/AIDS and HCV coinfection among 
the different age groups; HIV/AIDS proportion was highest among the 26-35 age groups and 
HCV coinfection was highest among the 36-45 age group. HCV coinfected patients tend to be 
older compared to the HIV infected only group. After examining the coinfected patients only, 
those ages 36-45, 46-55 and 56 and above had positive significant odds of having HIV/HCV 
coinfection compared to the 17-25 age group. Furthermore, this study showed that the 56 and 
above age group had 2.1 times odds of having HCV coinfection compare to the 17-25 age 
group. Most programs are targeting the younger age group (17-25), but this study showed that 
older people were more at risk for HCV coinfection may be due to some risk factors/ sexual 
risk behaviors and IDU; furthermore, thes persons have lived longer compare to young people 
with more opportunities to be exposed.  
The proportion of foreign-born individuals is lower among those coinfected with HCV 
and multivariate analysis showed that the foreign born had 0.7 times odds of having HCV 
coinfection compare to USA born persons with 95% CI= 0.4-0.9.  It is known that t foreign 
born individuals have higher odds of having HIV infection (table 3), but our study showed that 
the risk of HCV coinfection is lower. These results need to be investigated further for 
confirmation. 
The mortality rate was high among HCV coinfected persons; the current study 
concluded that having HCV coinfection increased by 1.87 times the odds of dying compared to 
having HIV infection only (OR=1.87; 95% CI: 1.42-2.45). Several studies have published 
similar results regarding an increase of the mortality rate among those coinfected with HCV  
(Prussing et al., 2015). This high mortality is likely related to liver damage and the acceleration 
to AIDS (Andreoni et al., 2012). 
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Of a total of 248 persons with HIV/HCV coinfection, 129 persons were infected with 
HCV after the HIV started compare to 119 persons who had HCV before the HIV infection. we 
could not figure out which group had the higher odds due to the sample size and the type of 
study design. Future studies are needed to determine which group is more at risk; these may 
help to focus effort for preventing the state of HCV coinfection. 
 
LIMITATIONS AND RECOMMENDATIONS 
Missing information and underreporting were on the limitation of this study. Many 
persons did not have all their information recorded making challenging the analysis process. 
Moreover, this fact decreased the sample size, and the consequence is the loss of power. 
Underreporting is a limitation because we could find the exact number of people with HCV 
coinfection. Due to the data collection method, we could not capture the real number of people 
moved out-Nebraska having coinfection and should be taken into consideration in the reporting 
electronic system.  
Based on the results of this study, an improved data surveillance of HCV infection, 
widespread adoption of electronic health record systems and electronic information exchange 
can provide a wealth of new data sources and better monitor the true incidence of HCV infection 
among people.  High-risk PLWHA should be monitored and targeted for preventive measures to 
prevent HCV coinfection.  Finally, there is a need for future studies to identify the best public 
health interventions to decrease the HCV coinfection among PLWHA in Nebraska. 
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CONCLUSION 
This study showed that the odds of having HCV coinfection were not statistically 
significant based on race. The odds of having HCV coinfection was significant with IDU used 
and increased in the case where IDU was associated to another risk sexual behavior, but 
surprisingly MSM did not show any increase odds of HCV coinfection compare to the 
heterosexual group. Furthermore, it is found that 36 years and above had higher odds of having 
HCV compare to 17-25 age group. The mortality was increased among HCV coinfected people. 
Future and better study designs are needed to better understand the epidemiology of some 
specific groups such as foreign-born. Future and better study designs are required to understand 
better some the burden of HCV coinfection among PLWHA in Nebraska. 
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